Overview
Beximco was, for most of Bangladesh's independent history, the country's best-known private conglomerate. It made generic medicines, spun yarn and sewed garments for Western brands, fired ceramics, built power plants and owned a television channel and a newspaper. Today it is two very different businesses under one name. Beximco Pharmaceuticals, listed in Dhaka and on London's AIM, still runs profitably. Most of the rest of the group has been under a court-ordered receiver since the fall of Sheikh Hasina's government in 2024, with factories shut and tens of thousands of jobs gone.
The company is inseparable from its co-founder Salman F. Rahman, who was both its vice-chairman and, from 2019 to 2024, the prime minister's cabinet-rank adviser on private industry.
History
The brothers A. S. F. Rahman and Salman F. Rahman founded Bangladesh Export Import Company in 1972, a year after a war of independence had left the new country short of almost everything. Trading came first. Manufacturing followed, and the most important step was Beximco Pharmaceuticals in 1976. Over the next decades it became one of Bangladesh's leading drug makers and one of its few pharmaceutical exporters, and in 2005 it became the first Bangladeshi company listed on London's Alternative Investment Market. In 1982 the brothers co-founded AB Bank, one of the country's first private banks.
The group then spread across the economy: a large vertically integrated textile and apparel business, Shinepukur Ceramics, energy projects, financial services, Independent Television and the English-language daily The Independent. In 2021 Beximco Pharma distributed the Oxford-AstraZeneca vaccine made by the Serum Institute of India under the Covishield name, and completed its purchase of Sanofi's Bangladesh business.
The turn came in August 2024. A student-led uprising forced Hasina from power, and Salman F. Rahman was arrested on 13 August. The High Court then ordered a receiver to take charge of Beximco Group assets because of the group's very large borrowings from state-owned banks. The Appellate Division upheld that order but suspended it for Beximco Pharmaceuticals. In February 2025 Bangladesh Bank executive director Khasru Parvez was named receiver.
How the business works
The healthy part of Beximco earns money the way most generic-drug makers do: it manufactures off-patent medicines in volume and sells them through pharmacies and hospitals at home, with a growing export business. For the year to 30 June 2025 Beximco Pharmaceuticals reported consolidated net revenue of about Tk 49.1 billion, up 10.7%, and net profit of Tk 699.88 crore, according to its results and The Business Standard. It recommended a 47.5% cash dividend.
The rest of the group depended on export garments and on bank credit, and that model has largely stopped. Reporting by The Daily Star and bdnews24.com put garment lay-offs at about 40,000 workers. In 2025 the government moved to close 12 group companies permanently, most of them garment units, and to sell mortgaged shares of Beximco Pharmaceuticals and Shinepukur Ceramics to pay workers' dues. A Tk 3,000 crore green sukuk issued by BEXIMCO Limited, with about Tk 2,800 crore still owed to investors, matures in December 2026; a Bangladesh Bank-led committee has proposed extending it to 2032.
Ownership and leadership
The founding family still holds the controlling stakes, but control in practice is split. A. S. F. Rahman chairs Beximco Pharmaceuticals and, under new boards approved by the securities regulator in 2026, BEXIMCO Limited and Shinepukur Ceramics. Salman F. Rahman was removed from all three listed boards in September and October 2026, reportedly with his consent. On 12 November 2026 Beximco Pharma named its long-time chief operating officer, S. M. Rabbur Reza, managing director, succeeding Iqbal Ahmed. Everything outside the pharmaceutical company answers to the receiver.
Controversies
ALLEGED: corruption, loan fraud and money laundering. Since his arrest Salman F. Rahman has been named in Anti-Corruption Commission loan-fraud cases, including one over Janata Bank lending, and investigators approved charge sheets in 17 money-laundering cases in November 2025 over about $97 million allegedly moved through export trade. None has reached a verdict, and he is entitled to the presumption of innocence.
ALLEGED: crimes against humanity. In January 2026 the International Crimes Tribunal framed charges accusing him of inciting killings during the 2024 uprising. He pleaded not guilty and the trial was continuing in late 2026.
PROVEN: a structural conflict of interest. No court ruling is needed to see the problem the group's critics described for years. A cabinet-rank adviser on industry was also vice-chairman of a conglomerate that borrowed from state banks and held national contracts, including the 2021 vaccine distribution role.
DISMISSED: the 2010–11 market crash. Rahman's name featured in the cases that followed Bangladesh's stock-market collapse, but he was acquitted around 2015.
Why it matters
Beximco shows how much of an industrial empire can rest on access to credit and to power, and how quickly that part unravels when power changes hands. Its pharmaceutical arm, the part built on manufacturing skill and export sales, is also the part still standing. For the full account of the founder's rise and fall, read Salman F. Rahman: Beximco and the Fortune Fused to the State.